Change in visual acuity at 1 year from baseline by treatment adjusted for starting visual acuity, age, gender and year of starting therapy by multivariate modelling
| Variable | Beta | 95% CI | p Value |
| Drug (posology) | |||
| Ranibizumab (three plus PRN) | ref | ||
| Aflibercept (fixed dosing or treat and extend) | 4.15 | 2.48 to 5.82 | 1.25e-06* |
| Starting visual acuity | −0.31 | −0.35 to −0.26 | 2e-16* |
| Age | −0.24 | −0.33 to −0.15 | 3.89e-07* |
| Female | −0.95 | −2.43 to 0.52 | 0.21 |
| Year of starting therapy | 0.23 | −1.08 to 1.53 | 0.73 |
*p-value <0.05.
PRN, pro re nata.